TBPH250117P10000
- 0.40
- 0.000.00%
Theravance Biopharma Newsroom
The Past Five Years for Theravance Biopharma (NASDAQ:TBPH) Investors Has Not Been Profitable
Theravance Biopharma to Participate in an Upcoming Investor Conference
A Quick Look at Today's Ratings for Theravance Biopharma(TBPH.US), With a Forecast Between $9 to $15
Theravance Biopharma | 10-Q: Q3 2024 Earnings Report
Baupost's Top Q3 Trades Include Jazz Exit, New Dollar General Stake
Theravance Biopharma Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Sales Results.
Theravance Biopharma Up Over 10%, on Pace for Largest Percent Increase Since January 2022 -- Data Talk
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
Theravance Biopharma (TBPH) Receives a Hold From Evercore ISI
H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $15
Buy Rating Reaffirmed for Theravance Biopharma Amid Positive Momentum and Strategic Initiatives
Balanced View on Theravance Biopharma: Strong Growth Amidst Financial Challenges and Strategic Uncertainty
Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript Summary
Theravance Biopharma: Strategic Review Committee to Assess Alternatives to Unlock Shareholder Value >TBPH
Theravance Biopharma: Board Announces Initiatives to Unlock Shareholder Value and Enhance Corporate Governance >TBPH
Theravance Biopharma Sees FY24 R&D Expense $30M-$36M; Share-Based Compensation $18M-$22M; SG&A $45M-$55M.
Theravance Biopharma Q3 2024 Adj. EPS $(0.26) Misses $(0.23) Estimate, Sales $16.900M Beat $15.344M Estimate
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Reports Q3 Revenue $16.9M
Theravance Biopharma | 8-K: Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
Express News | Theravance Biopharma Q3 Operating Income USD -10.837 Million